Centene and healthcare administration company Evolent Health expanded their partnership for oncology specialty care.
The payer will use Evolent oncology offerings for its Centene and WellCare Medicare Advantage programs, according to a March 29 Evolent news release.
Centene finalized its sale of Magellan Specialty Health to Evolent in January. Centene announced the sale in November and said it and Evolent would launch a multiyear partnership upon the closing of the deal. Centene said it will continue and expand its relationship with Magellan Specialty Health as well as its ongoing expansion of Evolent's oncology and end-of-life services.